Rotarod studies in the rat of the GABAA receptor agonist gaboxadol: Lack of ethanol potentiation and benzodiazepine cross-tolerance

European Journal of Pharmacology

Volumn 482, Issue 1-3, 2003, Pages 215-222

  Voss, Jeppe ^a   Sanchez, Connie ^a   Michelsen, Signe ^a   Ebert, Bjarke ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Cross tolerance; Ethanol; Flunitrazepam; GABAA receptor; Gaboxadol; Hypnotic; Indiplon; Rotarod; THIP; Zolpidem

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ALCOHOL; BENZODIAZEPINE DERIVATIVE; FLUNITRAZEPAM; GABOXADOL; INDIPLON; ZOLPIDEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSS TOLERANCE; DOSE RESPONSE; MALE; MOTOR COORDINATION; MOTOR DYSFUNCTION; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

EID: 0344305483     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.10.007     Document Type: Article

References (58)

1. Adkins C.E., Pillai G.V., Kerby J., Bonnert T.P., Haldon C., McKernan R.M., Gonzalez J.E., Oades K., Whiting P.J., Simpson P.B. Alpha4beta3delta GABA(A) receptors characterized by fluorescence resonance energy transfer-derived measurements of membrane potential. J. Biol. Chem. 276:2001;38934-38939.
2. Barnard E.A., Skolnick P., Olsen R.W., Mohler H., Sieghart W., Biggio G., Braestrup C., Bateson A.N., Langer S.Z. International union of pharmacology: XV. Subtypes of gamma-aminobutyric acid-A receptors: classification on the basis of subunit structure and receptor function. Pharmacol. Rev. 50:1998;291-313.
3. Bonnert T.P., McKernan R.M., Farrar S., le Bourdellès B., Heavens R.P., Smith D.W., Hewson L., Rigby M.R., Sirinathsinghji D.J., Brown N., Wafford K.A., Whiting P.J. Theta, a novel gamma-aminobutyric acid type A receptor subunit. Proc. Natl. Acad. Sci. U. S. A. 96:1999;9891-9896.
4. A receptors. Br. J. Pharmacol. 136:2002;965-974.
5. Chan A.W.K. Effects of combined alcohol and benzodiazepine: a review. Drug Alcohol Depend. 6:1984;341-349.
6. Crestani F., Martin J.R., Möhler H., Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br. J. Pharmacol. 131:2000;1251-1254.
7. Davies D.L., Benjanian M., Parker E.S., Morland J., Bolger M.B., Brinton R.D., Alkana R.L. Low-level hyperbaric antagonism of diazepam's locomotor depressant and anticonvulsant properties in mice. J. Pharmacol. Exp. Ther. 276:1996;667-675.
8. Davies D.L., Bolger M.B., Brinton R.D., Finn D.A., Alkana R.L. In vivo and in vitro hyperbaric studies in mice suggest novel sites of action for ethanol. Psychopharmacology. 141:1999;339-350.
9. 3H]zolpidem binding in rat brain. Eur. J. Pharmacol. 267:1994;243-247.
10. 3H]zolpidem binding in rat brain. Alcohol., Clin. Exp. Res. 19:1995;910-914.
11. Drover D., Lemmens H., Naidu S., Cevallos W., Darwish M., Stanski D. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/ pharmacodynamic profiles of zaleplon and zolpidem. Clin. Ther. 22:2000;1443-1461.
12. Ebert B., Wafford K.A., Whiting P.J., Krogsgaard-Larsen P., Kemp J.A. Molecular pharmacology of γ-aminobutyric acid type A receptor agonists and partial agonists in oocytes injected with different alpha, beta and gamma receptor subunit combinations. Mol. Pharmacol. 46:1994;957-963.
13. Ebert B., Thompson S.A., Saounatsou K., McKernan R., Krogsgaard-Larsen P., Wafford K.A. Differences in agonist/antagonist binding affinity and receptor transduction using recombinant human γ-aminobutyric acid type A receptors. Mol. Pharmacol. 52:1997;1150-1156.
14. A receptor ligands in the rat cortical wedge preparation - evidence for action at extrasynaptic receptors. Br. J. Pharmacol. 137:2002;1-8.
15. Fahey J.M., Pritchard G.A., Grassi J.M., Pratt J.S., Shader R.I., Greenblatt D.J. Pharmacodynamic and receptor binding changes during chronic lorazepam administration. Pharmacol. Biochem. Behav. 69:2001;1-8.
16. A agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans. Psychopharmacology. 130:1997;285-291.
17. Goa K.L., Heel R.C. Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs. 32:1986;48-65.
18. Günther U., Benson J., Benke D., Fritschy J.M., Reyes G., Knoflach F., Crestani F., Aguzzi A., Arigoni M., Lang Y. Benzodiazepine-insensitive mice generated by targeted disruption of the gamma 2 subunit gene of gamma-aminobutyric acid type A receptors. Proc. Natl. Acad. Sci. U. S. A. 92:1995;7749-7753.
19. Guthrie S., Cooper R.L., Thurman R., Linnoila M. Pharmacodynamics and pharmacokinetics of ethanol, diazepam and pentobarbital in young and aged rats. Pharmacol. Toxicol. 61:1987;308-312.
20. Haefely W. Biological basis of drug-induced tolerance, rebound and dependence. Contribution of recent research on benzodiazepines. Pharmacopsychiatry. 90:1986;353-361.
21. Klotz U. Drug interactions and clinical pharmacokinetics of flumazenil. Eur. J. Anaesthesiol. (Suppl. 2):1988;103-108.
22. Kuitunen T., Mattila M.J., Seppälä T. Actions and interactions of hypnotics on human performance: single doses of zopiclone, triazolam and alcohol. Int. Clin. Psychopharmacol. (Suppl. 2):1990;115-130.
23. A agonist THIP increases non-REM sleep and enhances non-REM sleep-specific delta activity in the rat during the dark period. Sleep. 20:1997;1099-1104.
24. A receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. Sleep. 22:1999;33-42.
25. A agonist THIP (gaboxadol) increases non-REM sleep and enhances delta activity in the rat. NeuroReport. 7:1996;2241-2245.
26. A) agonist 4,5,6,7-tetrahydroisoxazolo (4,5-c)pyridin-3-ol persistenly increases sleep maintenance and intensity during chronic administration to rats. J. Pharmacol. Exp. Ther. 293:2000;1084-1090.
27. A receptors in sleep regulation; different effects of muscimol and midazolam on sleep in rats. Neuropsychopharmacology. 15:1996;63-74.
28. A α1 receptors: involvement in sleep regulation and potential of selective agonists in the treatment of insomnia. CNS Drugs. 13:2000;185-199.
29. Langer S.Z., Arbilla S. Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification as omega receptor subtypes. Pharmacol. Biochem. Behav. 29:1988;763-766.
30. Langtry H.D., Benfield P. Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs. 40:1990;291-313.
31. MacLeod S.M., Giles H.G., Patzalek G., Thiessen J.J., Sellers E.M. Diazepam actions and plasma concentrations following ethanol ingestion. Eur. J. Clin. Pharmacol. 11:1977;345-349.
32. A-receptor subtypes really occur in the brain. Trends Neurosci. 19:1996;139-143.
33. McKernan R.M., Rosahl T.W., Reynolds D.S., Sur C., Wafford K.A., Atack J.R., Farrar S., Myers J., Cook G., Ferris P., Garrett L., Bristow L., Marshall G., Macaulay A., Brown N., Howell O., Moore K.W., Carling R.W., Street L.J., Castro J.L., Ragan C.I., Dawson G.R., Whiting P.J. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA-A receptor alpha-1 subtype. Nat. Neurosci. 3:2000;587-592.
34. A receptor function. J. Pharmacol. Exp. Ther. 246:1988;170-176.
35. Moriya F., Ishizu H. Interactive effects of ethanol on benzodiazepines levels in blood and brain of rat. Arukōru Kenkyū to Yakubutsu Izon. 27:1992;254-265.
36. 5-subunit creates novel type II benzodiazepine pharmacology. J. Neurochem. 54:1990;1802-1804.
37. A-benzodiazepine receptors produced in transfected cells. Science. 245:1989;1389-1392.
38. Ramsey V.A., Tietz E.I., Rosenberg H.C. Chronic flurazepam differentially regulates a behavioral effect of GABA agonists. Pharmacol. Biochem. Behav. 38:1991;659-663.
39. Rastogi S.K., Thyagarajan R., Clothier J., Ticku M.K. Effect of chronic treatment of ethanol on benzodiazepine and picrotoxin sites on the GABA receptor complex in regions of the brain of the rat. Neuropharmacology. 25:1986;1179-1184.
40. Roehrs T., Rosenthal L., Koshorek G., Mangano R.M., Roth T. Effects of zaleplon or triazolam with or without ethanol on human performance. Sleep Med. 2:2001;323-332.
41. Rosen A.S., Fournie P., Darwish M., Danjou P., Troy S.M. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm. Drug Dispos. 20:1999;171-175.
42. Rudolph U., Crestani F., Benke D., Brünig I., Benson J.A., Fritschy J.-M., Martin J.R., Bluethmann H., Möhler H. Benzodiazepines actions mediated by specific gamma-aminobutyric acid-A receptor subtypes. Nature. 401:1999;796-800.
43. Sanger D.J., Benavides J., Perrault G., Morel E., Cohen C., Joly D., Zivkovic B. Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: evidence for the functional significance of receptor subtypes. Neurosci. Biobehav. Rev. 18:1994;355-372.
44. Sanger D.J., Morel E., Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur. J. Pharmacol. 313:1996;35-42.
45. Schultz B., Aaes-Jørgensen T., Bøgesø K.P., Jørgensen A. Preliminary studies on the absorption, distribution, metabolism, and excretion of THIP in animal and man using 14C-labelled compound. Acta Pharm. Toxicol. (Cph.). 49:1981;116-124.
46. Sellers E.M., Naranjo C.A., Giles H.G., Frecker R.C., Beeching M. Intravenous diazepam and oral ethanol interaction. Clin. Pharmacol. Ther. 28:1980;638-645.
47. Seppälä T., Nuotto E., Dreyfus J.F. Drug-alcohol interactions on psychomotor skills: zopiclone and flunitrazepam. Pharmacology. 27(Suppl. 2):1983;127-135.
48. A receptor subtypes. Pharmacol. Rev. 47:1995;181-234.
49. Sieghart W., Schuster A. Affinity of various ligands for benzodiazepine receptors in rat cerebellum and hippocampus. Pharmacol. Biochem. Behav. 33:1984;4033-4038.
50. Sieghart W., Fuchs K., Tretter V., Ebert V., Jechlinger M., Höger H., Adamiker D. Structure and subunit composition of GABA(A) receptors. Neurochem. Int. 34:1999;379-385.
51. Squires R.F., Benson D.I., Braestrup C., Coupet J., Klepner C.A., Myers V., Beer B. Some properties of brain specific benzodiazepine receptors: new evidence for multiple receptors. Pharmacol. Biochem. Behav. 10:1979;825-830.
52. Storustovu S., Ebert B. Gaboxadol: in vitro interaction studies with benzodiazepines and ethanol suggest functional selectivity. Eur. J. Pharmacol. 467:2003;49-56.
53. Ticku M.K., Burch T.P., Davis W.C. The interactions of ethanol with the benzodiazepine-GABA receptor-ionophore complex. Pharmacol. Biochem. Behav. 18(Suppl. 1):1983;15-18.
54. Tietz E.I., Chiu T.H., Rosenberg H.C. Regional GABA/benzodiazepine receptor/chloride channel coupling after acute and chronic benzodiazepine treatment. Eur. J. Pharmacol. 167:1989;57-65.
55. A receptor: differential interaction of benzodiazepines and neuroactive steroids with ethanol. Psychopharmacology. 141:1999;77-82.
56. Wafford K.A., Whiting P., Kemp J.A. Functional modulation of cloned GABAA receptors expressed in Xenopus oocytes. Adv. Biochem. Psychopharmacol. 47:1992;75-79.
57. A receptor that determine ligand binding and modulation at the benzodiazepine site. Mol. Pharmacol. 52:1997;874-881.
58. Woods J.H., Katz J.L., Winger G. Benzodiazepines: use, abuse and consequences. Pharmacol. Rev. 44:1992;151-348.